Tempest Therapeutics held its 2026 Annual Meeting of Stockholders on November 9, 2026, where shareholders elected two Class II directors and ratified Ernst & Young LLP as the independent auditor. Stockholders also approved two key financing-related proposals under Nasdaq rules, including the potential issuance of shares to Lincoln Park Capital Fund and shares issuable upon the exercise of warrants from a September 2026 private placement.
Tempest Therapeutics reconvened and subsequently adjourned its special meeting of stockholders to November 12, 2026, to allow more time to solicit votes for a proposal to amend its charter. The proposal seeks to replace supermajority voting requirements and permit stockholder action by written consent, which requires a 75% affirmative vote to pass.
Tempest Therapeutics reconvened and subsequently adjourned its special meeting of stockholders to October 14, 2026, to allow more time to solicit votes for a proposal to amend its certificate of incorporation. The proposal, which requires a 75% supermajority for approval, seeks to replace existing supermajority voting requirements and permit stockholder action by written consent. While a quorum was present with 72.7% of outstanding shares represented, there were insufficient votes at the time of the meeting to pass the measure.